Sunshine Heart to Present at Upcoming Investor Conferences

Sunshine Heart to Present at Upcoming Investor Conferences

EDEN PRAIRIE, Minn., Nov. 6, 2013 (GLOBE NEWSWIRE) -- Sunshine Heart, Inc.
(Nasdaq:SSH) today announced that the company is scheduled to present a
corporate update at the following upcoming investor conferences for the
balance of 2013:

  *2013 Credit Suisse Healthcare Conference

  Presentation: Tuesday, November 12, 2013 at 9:30 AM MST at The Phoenician in
  Scottsdale, Arizona. Breakout session to immediately follow presentation at
  10:00 AM MST

  Presenting: Jeff Mathiesen, Chief Financial Officer

  *2013 Canaccord Genuity Medical Technology & Diagnostics Forum

  Presentation: Thursday, November 14, 2013 at 3:30 PM EST at the Westin Grand
  Central in New York, New York

  Presenting: Jeff Mathiesen, Chief Financial Officer

  *Barclays Select Series 2013: Growth Conference

  Presentation: Tuesday, November 19, 2013 at 8:20 AM EST at 745 7^th Ave in
  New York, New York (Club Room I)

  Presenting: Kevin Bassett, Senior Vice President of Technology and

  *Piper Jaffray 25^th Annual Healthcare Conference

  Presentation: Tuesday, December 3, 2013 at 1:30 PM EST at the New York
  Palace Hotel in New York, New York (Rutherford Room)

  Presenting: Dave Rosa, Chief Executive Officer

  *Oppenheimer 24^th Annual Healthcare Conference

  Presentation: Wednesday, December 11, 2013 at 2:10 EST at the Crowne Plaza
  Hotel in New York, New York

  Presenting: Jeff Mathiesen, Chief Financial Officer

About the C-Pulse^® Heart Assist System

The C-Pulse Heart Assist System, or C-Pulse System, an investigational device
in the United States, Canada and countries that do not recognize the CE mark
approval, utilizes the scientific principles of intra-aortic balloon
counterpulsation applied in an extra-aortic approach to assist the left
ventricle by reducing the workload required to pump blood throughout the body,
while increasing blood flow to the coronary arteries. Combined, these
potential benefits may help sustain the patient's current condition or, in
some cases, reverse the heart failure process, thereby potentially preventing
the need for later-stage heart failure devices, such as left ventricular
assist devices (LVADs), artificial hearts or transplants. It may also provide
relief from the symptoms of Class III and ambulatory Class IV heart failure
and improve quality of life and cardiac function. Based on the results from
our feasibility trial, we also believe that some patients treated with our
C-Pulse System will be able to stop using the device due to sustained
improvement in their condition as a result of the therapy.

Caution: Investigational device, limited by Federal (or United States) Law to
Investigational use.

About Sunshine^® Heart

Sunshine Heart, Inc. is a medical device company focused on developing,
manufacturing and commercializing the C-Pulse System for treatment of Class
III and ambulatory Class IV heart failure. Sunshine Heart has completed an
approved U.S. Food and Drug Administration (FDA) feasibility clinical trial of
the C-Pulse System and presented the results in November 2011. In March 2012,
the FDA notified the Company that it could move forward with an
investigational device exemption (IDE) application. Sunshine Heart received
unconditional approval from the FDA in November 2012 to initiate its pivotal
trial. In July 2012 Sunshine Heart received CE Mark approval for its C-Pulse
System in Europe. Sunshine Heart is a Delaware corporation headquartered in
Minneapolis with a wholly owned subsidiary in Australia. The Company has been
listed on the NASDAQ Capital Market since February 2012.

Forward-Looking Statements

Certain statements in this release are forward-looking statements that are
based on management's beliefs, assumptions, expectations, and information
currently available to management. All statements that address future
operating performance, events or developments that we expect or anticipate
will occur in the future are forward-looking statements, including, without
limitation, future clinical trial activities and results including patient
enrollment in trials. These forward-looking statements are subject to numerous
risks and uncertainties, including, without limitation, the possibility that
our clinical trials do not meet their enrollment goals, meet their endpoints
or otherwise fail, that regulatory authorities do not accept our application
or approve the marketing of the C-Pulse System, the possibility that we may be
unable to raise the funds necessary for the development and commercialization
of our products, that we may not be able to commercialize our products
successfully in the European Union and the other risk factors described under
the caption "Risk Factors" and elsewhere in our filings with the Securities
and Exchange Commission. You should not place undue reliance on
forward-looking statements because they speak only as of the date when made
and may turn out to be inaccurate. We do not assume any obligation to publicly
update or revise any forward-looking statements, whether as a result of new
information, future events or otherwise. We may not actually achieve the
plans, projections or expectations disclosed in forward-looking statements,
and actual results, developments or events could differ materially from those
disclosed in the forward-looking statements.

CONTACT: For further information, please contact:
         Laura Forman
         Blueprint Life Science Group
         T: +1-415-375-3340
         Jeff Mathiesen
         Chief Financial Officer
         Sunshine Heart, Inc.
         T: +1-952-345-4200

Sunshine Heart logo
Press spacebar to pause and continue. Press esc to stop.